Orchid receives USFDA node for new drug

Orchid receives USFDA node for new drug
PTI
Comment E-mail Print Share
First Published: Thu, Dec 04 2008. 03 38 PM IST
Updated: Thu, Dec 04 2008. 03 38 PM IST
Mumbai: Orchid Chemicals & Pharmaceuticals today said it has received US administration approval for a drug used for the treatment of acute mania, manic episodes.
The company has received approval from the US Food and Drug Administration for Divalproex Sodium Delayed, Orchid Chemicals & Pharmaceuticals said in a filing to the Bombay Stock Exchange.
Mania is a severe medical condition characterised by extremely elevated mood, energy, unusual thought patterns and sometimes psychosis. Divalproex Sodium Delayed-release tablets will be available in strengths 125 mg, 250 mg and 500 mg, the filing added.
Shares of the company were trading at Rs84, up 3% on the BSE.
Comment E-mail Print Share
First Published: Thu, Dec 04 2008. 03 38 PM IST